GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:01:04 2024-04-24 am EDT			5-day change	1st Jan Change
1,655 ^GBX	+0.24%		+4.09%	+14.12%

09:12am	GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	MT
08:16am	GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	RE

Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010.

February 02, 2023 at 06:49 am EST

From October 1, 2022 to December 31, 2022, the company has repurchased 2,941,079 shares, representing 2.58% for $434.99 million. With this, the company has completed the repurchase of 91,268,933 shares, representing 64.21% for $8,192.56 million under the buyback announced on October 20, 2010.

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	GSK PLC	1,655 GBX	+0.24%	+4.09%	83.92B
	QUEST DIAGNOSTICS INCORPORATED	136.7 USD	+5.08%	+7.28%	15.18B

Latest news about GSK plc

GSK Secures US FDA's Priority Review for Expanded Use of Endometrial Cancer Treatment	03:12am	MT
GSK Says U.S. FDA Accepts New Indication Filing For Jemperli	02:16am	RE
Edwards Lifesciences Corporation: The story continues	Apr. 23
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
GSK Reports Positive Data for Gonorrhea Treatment Gepotidacin, Shingles Vaccine Shingrix	Apr. 17	MT
GSK: positive clinical results for gonorrhea	Apr. 17	CF
Gsk plc Announces New Long-Term Data Show Shingrix Continues to Provide High Protection Against Shingles in Adults Aged 50 and over for More Than A Decade	Apr. 17	CI
GSK: shingles virus effective for over 10 years	Apr. 17	CF
GSK hails data on Shingles vaccine and gonorrhoea treatment	Apr. 17	AN
GSK's Uncomplicated Urogenital Gonorrhea Treatment Meets Primary Endpoint in Late-stage Trial	Apr. 17	MT
GSK's Shingles Vaccine Shows High Efficacy Among Older Adults in 11-Year Follow-Up Trial	Apr. 17	MT
GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin	Apr. 17	CI
China GDP Beat Fails to Boost Sentiment as UK's FTSE 100 Index Sheds Nearly 2%	Apr. 16	MT
GSK Says US FDA Accepts Meningococcal Vaccine Candidate for Regulatory Review	Apr. 16	MT
GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY Vaccine Candidate	Apr. 16	CI
GSK: vaccine accepted for FDA review	Apr. 16	CF
GSK's latest meningitis vaccine accepted for review by US regulator	Apr. 16	AN
GSK Says FDA Accepts GSK Meningitis Vaccine Candidate File	Apr. 16	RE
US FDA Accepts GSK's Meningococcal Disease Vaccine Candidate for Regulatory Review	Apr. 16	MT
Pfizer RSV shot meets goals in trial of high-risk adults under age 60	Apr. 09	RE
GSK : Barclays sticks Neutral	Apr. 08	ZD
Barclays Lifts GSK PT, Maintains Equalweight Rating	Apr. 08	MT
Wizz Air raised; HSBC cuts Rentokil to 'hold'	Apr. 08	AN
CureVac Says Phase 2 Interim Data Show Multivalent Flu Vaccine Candidate Boosts Antibody Titers	Apr. 04	MT
GSK : Barclays reiterates its Neutral rating	Apr. 04	ZD

Chart GSK plc

Duration

Period

More charts

Company Profile

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.

Sector

Pharmaceuticals

Calendar

2024-04-29 - European Society of Clinical Microbiology and Infectious Diseases Meeting

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

GSK PLC : 2023 ended on a strong note; medium- to long-term guidance raised

February 02, 2024 at 09:40 am EST

More Strategies

Ratings for GSK plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

16.51 GBP

Average target price

20.06 GBP

Spread / Average Target

+21.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GSK PLC	+14.12%	83.92B
ELI LILLY AND COMPANY	+27.92%	672B
NOVO NORDISK A/S	+27.13%	570B
JOHNSON & JOHNSON	-4.59%	360B
MERCK & CO., INC.	+16.38%	321B
ABBVIE INC.	+9.39%	300B
ASTRAZENECA PLC	+7.38%	217B
NOVARTIS AG	+5.66%	199B
ROCHE HOLDING AG	-8.30%	204B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010.

Stocks mentioned in the article

EPS Revisions